A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: Low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C

International Braz J Urol

Volumn 34, Issue 1, 2008, Pages 117-118

  Bohle, Andreas ^a  

^a HELIOS AGNES KARLL HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41549143892     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (0)